Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk
 

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

More...